Full-Time

Senior Electrical Engineer

Posted on 5/11/2026

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$165k - $175k/yr

+ Stock Options + Variable Incentive Plan

Pleasanton, CA, USA

In Person

Willing to travel domestically and internationally up to 10%.

Category
Electrical Engineering (2)
,
Required Skills
Altium
Python
Risk Management
C/C++
Requirements
  • Bachelor’s degree in Electrical Engineering. Master’s preferred.
  • 8+ years of experience in electronic subsystem design in a regulated product environment; working knowledge of IEC 60601‑1, IEC 60601‑1‑2, and ISO 14971 concepts strongly preferred.
  • Analog and mixed‑signal circuit design (sensor front‑ends, signal conditioning).
  • Power electronics and power management (DC‑DC, linear regulation, protection).
  • PCBA design using modern Electrical Design Automation tools (schematic capture, layout review). Altium experience preferred.
  • Design of electrical interfaces for closed‑loop control system components (sensors, pumps, valves, heaters). Exposure to manufacturing, Design for Manufacturability/ Design for Testing, and field failure analysis of these interfaces strongly preferred.
  • Hands‑on prototyping, debugging, and lab test methodologies.
  • Understanding of EMI/EMC, grounding, and cabling best practices.
  • Experience in embedded systems design and hardware/software co‑
  • Proficiency in embedded software development (C/C++) and scripting for hardware automation and data analysis (Python). Experience with STM32 applications preferred.
  • Prior experience implementing closed‑loop control concepts (PID tuning, stability, disturbance rejection), with exposure to sensor calibration, drift management, and fault detection strategies.
  • Familiarity with design controls, design reviews, and change management.
  • Experience supporting requirements definition, verification testing and risk management. Application of these concepts to safety‑critical or redundant system design preferred.
  • Prior ownership of hardware through full lifecycle (concept through sustaining).
  • Proven ability to lead technical workstreams, including experience managing and reviewing work performed by external contractors or partners.
  • Strong documentation, presentation, and cross‑functional communication skills.
  • Must be self‑directed, self‑motivated and be able to multi‑task in a fast-paced environment with multiple priorities.
  • Ability to travel domestically and internationally up to 10% of the time.
Responsibilities
  • Develop electronic subsystems for a range of sensing, controls and communications applications in medical devices (disposable and capital).
  • Translate system‑level requirements into schematics, PCBAs, cable assemblies, and interface definitions.
  • Define electrical architectures including power distribution, sensing, actuation, safety interlocks, and diagnostics.
  • Design low‑noise analog, mixed‑signal, high-speed and power electronics PCBAs for sensors, actuators, control and communication electronics.
  • Specify and design custom cable harnesses (signal, power, shielding, grounding) suitable for medical environments.
  • Ensure EMI/EMC robustness and compliance with applicable medical standards (e.g., IEC 60601‑1‑2).
  • Select sensor, actuator, power electronics, and protection components for controls systems with attention to accuracy, drift, long term reliability, environmental exposure (heat, fluids, cleaning agents), component lifecycle, and applicable derating/tolerancing
  • Prototype and debug embedded control algorithms for real-time closed-loop control systems (PID, feed forward, fault detection, control limits)
  • Collaborate with firmware/software teams to define hardware/firmware interfaces and control strategies
  • Support bring-up, tuning, and characterization using lab instrumentation and test fixtures.
  • Support electrical and system‑level verification and validation testing, including IEC 60601-1 and 60601-1-2 compliance testing
  • Contribute to risk analyses (FMEA) with focus on safety‑critical failures.
  • Support troubleshooting during integration, verification testing, and clinical simulation
  • Provide technical oversight to contract design houses and manufacturing partners, including review of schematics, layouts, design changes, test plans, and documentation, ensuring adherence to design intent, quality expectations, and regulatory requirements
  • Interact with suppliers and internal operations representatives to perform design transfer, root cause investigation, component lifecycle management, and continuous improvement.
  • Partner closely with clinical development engineering, product management, quality, regulatory and other cross-functional teams to bring designs to the market.
  • Mentor junior and non-specialist engineering talent, promoting a collaborative and high-performance work environment.

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.